National Tuberculosis Controllers Association

NTCA Updates

Donna Wegener, MA

Peter Davidson, PhD

Outline

- TB drug supply, availability & affordability
- LTBI reporting & guidelines
- TB Survivor communications training
- Congressional meetings & briefings



TB Drug Supply, Availability & Affordability

- · High risk for shortage or price increase
 - Rifapentine (1); Rifabutin (3); Pyrazinamide (2)
 - Cycloserine (1; 2,248% price increase in 2015)
 - 7/17 WHO Essential Medicines at risk for price increase are for TB
- Supply affected by ingredients, manufacturing, and distribution
- · Price affected by corporate policy, acquisition, and availability of generics

Alpern et al. DOI: 10.1056/NEJMp1601559



TB Drug Supply, Availability & Affordability

- Workgroup
 - CDC & ACET: policy, political support
 - PHAC: insights from Canada
 - TAG: policy & advocacy support
 - NASTAD: experience w/ AIDS
 - Drug Assistance Program
 - USAID: interface w/ GDF
 - GDF: global supplier of quality drugs at negotiated price



TB Drug Supply, Availability & Affordability

- NTCA, TAG, Sanofi
 - Reduced price of rifapentine \$51/box to \$32/pack
 - Packaging customized for U.S. use and needs
 - Working to expand access to other Sanofi TB drugs (e.g. rifamate: rifampin/isoniazid combo)
- NTCA, CDC, HHS Supply Service Center
 - Emergency stockpile: rifampin; isoniazid; rifapentine; capreomycin; amikacin
 - Funded for 2017 & 2018; future ???
- NTCA, CDC, TAG, USAID
 - Harmonize with and procure (some) TB drugs through GDF Would guarantee availability and price equal or lower than $340 \mbox{B}$
 - Test if this could work (isoniazid, rifampin, kanamycin, levofloxacin)



LTBI Reporting & Guidelines

- CDC estimates 13M people w/ LTBI, but no standard case definition or approach for surveillance
 - Need to quantify true burden of LTBI in U.S. to achieve TB Elimination
 - CDC already developing surveillance systems for LTBI; likely to deploy by/during 2020



NTCA LTBI workgroup: LTBI case classification

- Suspect
 - positive TST or IGRA, AND
 - negative culture, if performed
- Confirmed
 - positive TST or IGRA, AND
 - negative culture, AND
 - no clinical evidence compatible w/ TB disease, AND
 - normal chest x-ray or CT, OR
 - abnormal radiology consistent w/ TB disease with culture negative for MTB complex AND TB disease clinically ruled out
- Pending review by CSTE in June, 2017

LTBI Reporting & Guidelines

- CDC, ATS & IDSA began writing LTBI guidelines in 2011. Process stalled (many reasons), and in 2015 CDC asked NTCA
 - physicians to develop a companion statement to provide key points and interpretations
- Guidelines nearly complete, but ATS withdrew in December, 2016 and IDSA withdrew in February, 2017
 - CDC has asked NTCA physicians to lead completion of guidelines

•

- CDC, NTCA and principal authors are discussing next steps Current plan is to publish a document within 6 months, if possible
- Will publish companion statement as interim guidance if full version is not ready (most likely scenario)
- * A guideline, a guideline! My kingdom for a guideline!















2017 TB Survivor Hill Day

- Tomorrow, March 21, 2017
- TB Survivors from:
 - KS, WI, NJ, NY, CO, WA, VA, NH, NC, FL, MA, MO
 - MDR-TB and Drug-sensitive TB
 - TB infection (a wife and a mother)
- Sponsored by TB organizations:
 - ATS, Aeras, RESULTS, NTCA, TB Alliance

2017 TB Survivor Communications Training

- April 18 in Atlanta, GA (pre-conference meeting)
 - Opportunity to stay and attend some/all of the 2017 NTC, if interested
- Nominations being collected from US TB programs
 - Funds to support 10-12 survivors from across the US







Congressional Briefing -

- NTCA sponsorship
- Focus on domestic TB challenges
- prevention
- TB deaths identified as a failure of the US healthcare system



2017 World TB Day Briefings

- Two events planned both co-sponsored by NTCA
 - Senate March 21
 - House March 24
- Senate Briefing focuses on pediatric TB and will be moderated by Ken Castro (former director of CDC Division of TB Elimination)
- House Briefing moderated by Bob Belknap (NTCA immediate past president)
- <u>Purpose of both</u> education about domestic and global TB challenges!

Action Alert!

- FY18 appropriations process
 - Let Washington know what is needed to eliminate TB in the US
 - Strong public health infrastructure
 - National prevention initiative
 - Focus on Anti-Microbial Resistance must include MDR and XDR-TB
 - Mono resistance increasingly a concern

Get involved!

Become a member of NTCA

ntca@tbcontrollers.org www.tbcontrollers.org/membership 678-503-0503 NTO